Stage III Breast Cancer Recruiting Phase 1 / 2 Trials for Atezolizumab (DB11595)

IndicationStatusPhase
DBCOND0031775 (Stage III Breast Cancer)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03566485Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerTreatment